Hims & Hers Shares Tumble as Profit Miss Overshadows Revenue Growth

Profitability Pressures Emerge Despite Sales Surge

The telehealth sector faced a stark reminder of its volatility as Hims & Hers Health, Inc. saw its stock decline sharply following a disappointing quarterly earnings report. While the company achieved record revenue, a significant profit shortfall and emerging competitive pressures in the weight-loss medication space spooked investors, raising questions about its near-term growth trajectory.

For the third quarter of 2025, the company’s financial performance presented a conflicting picture. On one hand, Hims & Hers surpassed revenue expectations and subsequently raised its full-year 2025 outlook, projecting sales between $2.335 billion and $2.355 billion. This represents a robust year-over-year increase of nearly 60%.